Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2000-04-20
2002-10-22
Kemmerer, Elizabeth (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000, C530S350000, C530S351000, C424S184100, C424S198100, C424S085100
Reexamination Certificate
active
06468960
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to compositions and methods for enhancing angiogenesis. More particularly, the invention relates to the use of the Mts-1 gene or Mts-1 protein for enhancing angiogenesis in human and animal subjects.
BACKGROUND OF THE INVENTION
Angiogenesis is a process by which new blood vessels are generated into a tissue or organ. Angiogenesis in rarely observed in normal tissues in humans and animals. Angiogenic factors from pathological tissues of various kinds have been characterized and isolated, such as those from solid tumors (Folkman et al.
J. Exp. Med.
133: 275, 1971), from synovial fluid (Brown et al.,
Lancet
I: 682:685, 1980), from human mayocardial infarcts (Kumar et al.,
Lancet
II: 364-367, 1983), from the vitreous fluid of humans with diabetic retinopathy and in the retinas of animals (Hill et al., Experientia 39: 583-585, 1983; D. Amore et al.,
Proc. Natl. Acad. Sci. USA
78: 3068-3073, 1981; Kissun et al.,
Br. J. Ophth.
66: 165-169, 1982), and from wound fluid (Branda et al.,
Proc. Natl. Acad.Sci. USA
79: 7773-7777, 1982).
Endothelial cells and pericytes, surrounded by a basement membrane, form capillary blood vessels. Angiogenesis begins with the erosion of the basement membrane by enzymes released from endothelial cells and leukocytes. The endothelial cells, which line the lumen of blood vessels, then protrude through the basement membrane. Angiogenic stimulants induce the endothelial cells to migrate through the eroded basement membrane. The migrating cells formula “sprout” off the parent blood vessel, where the endothelial cells undergo mitosis and proliferate. Eventually, the endothelial sprouts merge with each other to form capillary loops, creating the new blood vessel.
For a general review of angiogenisis, see Maciag, T.,
Molecular and Cellular Mechanisms of Angiogenesis
, in IMPORTANT ADV. ONCOL., pp. 85-98, 1990.
Mouse, rat and human Mts-1 genes have been previously identified and isolated (Linzer et al.,
Proc. Natl. Acad.Sci. USA
80: 4271-4275, 1983, Barraclogh et al., J. Mol. Biol. 198: 13-20, 1987 and U.S. Pat. No. 5,798,257 to Zain et al.). The Mts-1 protein, as a calcium binding protein, is believed to have a role in cell growth and myoepithelial cell differentiation. U.S. Pat. No. 5,798,257 discloses that the mammalian Mts-1 gene is expressed at 10-100 fold higher levels in metastatic cells compared to non-metastatic cells and normal cells, and thus, that an increased expression of the Mts-1 gene within a cell or tissue is diagnostic of metastatic cancer. The role of Mts-1 in angiogenesis has not been reported prior to the present invention.
SUMMARY OF THE INVENTION
The present inventors have uniquely identified that the Mts-1 protein stimulates angiogenesis. Accordingly, the present invention is directed to the use of angiogenic Mts-1 components in therapeutic compositions and methods for enhancing angiogenesis in a subject in need thereof.
The therapeutic compositions and methods of the present invention are useful for any situations in which angiogenesis is inadequate and is clinically required, such as damaged tissues or organs, or transplanted tissues or organs. The compositions and methods of the present invention are particularly useful for patients suffering a cardiac condition (e.g., patients after bypass surgery or heart transplant), patients suffering tissue damage in the skin, gastrointestinal tract, urinal tract, as well as a vascular tissues resistant to vascularization such as the knee, the wrist or the joint, patients who have suffered a stroke and any other patients in need of angiogenesis.
An angiogenic composition of the present invention can include an Mts-1 component, e.g., an Mts-1 protein, a functional fragment or analog of an Mts-1 protein, as well as nucleic acid molecules encoding such proteins, fragments or analogs.
Angiogenic compositions of the present invention can suitably include other substances that are appropriate or desirable for angiogenesis. These substances can include any other angiogenic compounds, growth hormones, growth factors, biologically active segments of growth factors, interleukins, polysaccharides, or mixtures thereof.
Angiogenic Mts-1 components suitable for use in the present methods are preferably provided in a pharmaceutically acceptable carrier, such as oils, water, saline solutions, gel, lipids, liposomes, resins, porous matrices, binders, fillers and the like, or combinations thereof.
The angiogenic compositions can be administered to a subject in need of angiogenesis by standard routes, including the oral, ophthalmic, nasal, topical, transdermal, parenteral, intracranial, intracerebral, intraspinal, intravaginal, intrauterine, or rectal route, or by injection or surgical implantation proximate to a preselected tissue or organ site.
REFERENCES:
patent: 5798257 (1998-08-01), Zain et al.
Skolnick et al. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotech 18(1): 34-39, 2000.*
Bork, A. Powers and pitfalls in sequence analysis: the 70% hurdle. Genome Res 10: 398-400, 2000.*
Doerks et al. Protein annotation: detective work for function prediction. Trends in Genetics 14(6):248-250, 1998.*
Smith et al. The challenges of genome sequence annotation or “The devil is in the details”. Nature Biotech 15: 1222-1223, 1997.*
Brenner, S.E. Errors in genome function. Trends in Genetics 15(4): 132-133, 1999.*
Bork et al. Go hunting in sequence databases but watch out for the traps. Trends in Genetics. 12(10): 425-427, 1996.*
Wells. J.A. Additivity of mutational effects in proteins. Biochemistry 29 (37): 8509-8517, 1990.*
Ngo et al. Computational complexity, protein structure prediction, and the Levinthal paradox. The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495, 1994.*
Simons et al. Clinical trials in coronary angiogenesis: issues, problems, consensus. Circulation 102: 73-86, 2000.*
Pettit et al. The development of site-specific drug-delivery systems for protein and peptide biopharmaceuticals. Trends Biotechnol 16: 343-349, 1998.*
Lazarous DF, Shou M, et al. Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovascular Research 36 (1997) 78-85.*
Ford, H.L., et al. (1995) “Interaction of metastasis associated Mts1 protein with nonmuscle myosin”,Oncogene10:1597-1605.
Gimbrone, M.A. Jr., et al. (1972) “Tumor Dormancy In Vivo by Prevention of Neovascularization”,The Journal of Experimental Medicine136:261-276.
Klingelhöfer, J., et al. (1997) “Expression of the Metastasis-Associated mts1 Gene During Mouse Development”,Development Dynamics210:87-95.
Kriajevska, M., et al. (1998) “Metastasis -associated Mts1 (S100A4) Protein Modulates Protein Kinase C Phosphorylation of the Heavy Chain of Nonmuscle Myosin”,The Journal of Biologica Chemistry273 (16) :9852-9856.
Folkman, J., et al. (1989) “Induction of angiogenesis during the transition from hyperplasia to neoplasia”,Nature339:58-61.
Kriajevska, M.V., et al. (1994) “Non-muscle Myosin Heavy Chain as a Possible Target for Protein Encoded by Metastasis-related mts-1 Gene”,The Journal of Biological Chemistry269(31):19679-19682.
Schäfer, B.W., et al. (1996) “The S100 family of EF-hand calcium-binding proteins: functions and pathology”,TIBS21:134-140.
Skobe, M., et al. (1997) “Halting angiogenesis suppresses carcinoma cell invasion”,Nature Medicine3(11):1222-1227.
Takenaga, K., et al. (1994) “Involvement of S100-related Calcium-binding Protein pEL98 (or mts1) in Cell Motility and Tumor Cell Invasion”,Jpn. J. Cancer Res.85:831-839.
Watanabe, Y., et al. (1993) “Calvasculin, as a factor affecting the microfilament assemblies in rat fibroblasts transfected by src gene”,FEBS324(1):51-55.
Zimmer, D.B., et al. (1995) “The S100 Protein Family: History, Function, and Expression”,Brain Research Bulletin37(4):417-429.
Ambartsumian Noona
Lukanidin Eugene M.
Kemmerer Elizabeth
Prolifia Inc.
Scully Scott Murphy & Presser
LandOfFree
Therapeutic compositions and methods for enhancing angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic compositions and methods for enhancing angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compositions and methods for enhancing angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2995010